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See Article, pages 334–341Hepatocellular carcinoma (HCC) is the ﬁfthmost com-
mon cause of cancer deaths worldwide [1]. In the United
States and Europe the incidence of HCC is rising, and is
expected to increase by another 81% by the year 2020 pri-
marily due to the hepatitis C epidemic [2]. The strongest
risk factors for the development of HCC are chronic hep-
atitis B (HBV) and hepatitis C (HCV) virus infection, as
well as cirrhosis of any cause [3]. Other risk factors that
have been reported include exposure to aﬂatoxin [4], alco-
hol, tobacco, obesity [5], and diabetes [6]. HCC has been
well documented to cluster within families [7,8], but this
has been primarily in regions where HBV is endemic
andmay have been related to a high prevalence of chronic
HBV infection in those families. Only one case-control
study of family history and HCC has been performed in
an areawith a low prevalence ofHBV, involving 287 cases
and 450 controls in northern Italy [9]. Given the rising
incidence of HCC in the United States and Europe, fur-
ther investigation into the contribution of genetic factors
to this disease is needed. Such studies could pave the way
towards a better understanding of the pathogenesis of
HCC and potential therapeutic targets.
In this issue of the Journal, Hassan et al. report on a
case-control study of family history of HCC involving
347 cases and 1075 controls, of which 190 cases and
1039 controls had no HBV or HCV markers [10]. The
HCC cases were all pathologically conﬁrmed, and the
control subjects were family members of patients at their0168-8278/$34.00  2008 European Association for the Study of the Liver.
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authors found that having a ﬁrst degree relative with
liver cancer was associated with a 3.9-fold increased risk
of having HCC (95% conﬁdence interval 1.4–11.5), com-
pared to no family history of liver cancer, after adjusting
for numerous factors including age, gender, race, educa-
tion, tobacco, alcohol, diabetes, and viral hepatitis.
Among the subgroup without viral hepatitis, family his-
tory of liver cancer was associated with a 4.1-fold
increased risk of having HCC (95% conﬁdence interval
1.3–12.9) in multivariate analysis.
The strengths of this study include the relatively large
sample size, the pathologic conﬁrmation of HCC diagno-
sis, the structured and validated family history interview,
and the attempt to control for numerous potential con-
founders. One limitation of the study is the potential
for recall bias, which is inherent in any study of this
design [11]. Recall bias occurs when subjects are asked
to recall past events such as family history, and may be
more likely to report those events which are salient to
their current diagnosis. The magnitude of bias in this
study is likely small, since subjects were not informed
about the aims of the study and the family history ques-
tions were nested in a long list of other questions. How-
ever, completely eliminating this bias would require a
prospective longitudinal cohort study. Another limita-
tion, as the authors point out, is the lack of information
on family history of liver diseases such as genetic hemo-
chromatosis and alpha-1-antitrypsin deﬁciency, which
are associated with increased risk of HCC. This is partic-
ularly relevant in patients without viral hepatitis. A third
limitation is the lack of weight measurement in cases and
controls. Obesity has been shown to be a risk factor for
HCC in some studies [5], and since obesity tends to runPublished by Elsevier B.V. All rights reserved.
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looked. Despite these limitations, the authors should be
congratulated on their performance of a large well-
designed study on the importance of family history of
liver cancer in a Western population.
Although ﬁrm conclusions should never be drawn
based upon subgroup analysis, some interesting observa-
tions arose from this studywhichmerit further discussion.
First, a family history of cancer of any type did not appear
to increase the risk of having HCC, suggesting a genetic
defect speciﬁc for the liver rather than mutation of a
widely expressed tumor suppressor gene such as p53 [12]
or DNA synthesis gene such as thymidylate synthase
[13]. Second, having a sibling with HCC appeared to con-
fer a much higher risk than having a parent with HCC,
suggesting the possibility of a recessive inheritance pat-
tern. While these two observations seem to support a role
for genetic factors, it is also possible that environmental
factors, e.g. dietaryhabits or exposure to carcinogens such
as aﬂatoxinmay contribute to familial clustering ofHCC.
Cirrhosis due to non-alcoholic fatty liver disease
(NAFLD) is becoming an increasingly important cause
of HCC [14]. Numerous studies have shown that risk fac-
tors for NAFLD such as obesity, diabetes, and dyslipide-
mia run in the family [15], possibly due to a combination
of genetic factors and shared lifestyle. With increasing
prevalence of obesity and NAFLD in the US and world-
wide, future studies should determine if family history of
NAFLD, diabetes or metabolic syndrome is a risk factor
for development of HCC. A ﬁnal interesting observation
was that family history of liver cancer was only a risk fac-
tor for HCC in men (adjusted odds ratio 9.2, 95% conﬁ-
dence interval 1.9–45.3) but not in women (adjusted
odds ratio 1.6, 95%conﬁdence interval 0.3–8.7). This ﬁnd-
ing has been consistently seen in other studies, including a
prospective longitudinal 90,000-person cohort study in
China [16]. Hassan et al. postulated a gene–environment
interaction such as cigarette smoking, which is more com-
mon among men and could interact synergistically with
inherited genetic mutations. Of note, this hypothesis
could be tested statistically by including an interaction
term between family history and cigarette smoking in
the multivariate model. Another possibility is that the
hepato-carcinogenesis pathway may be diﬀerent between
men and women. For example, HCC in men is associated
with shorter CAG repeats in the androgen receptor gene,
but HCC in women is conversely associated with longer
CAG repeats [17]. Hormonal diﬀerences may account
for the higher incidence of HCC in men. Clearly, gender
diﬀerences in the genetics of HCC are an important area
for further study.
In summary, Hassan et al. have strengthened the case
for family history of liver cancer as a risk factor for
HCCeven among familieswithout viral hepatitis. Future
longitudinal cohort studies should gather detailed family
histories to determine the role of genetic vs. environmen-tal factors in familial clustering of HCC. These studies
should includegeneticproﬁlingto identify thegenetic fac-
tors associated with increased risk of HCC. Data from
these studiesmay improveourunderstandingof thepath-
ogenesis of HCC, may help identify targets for rational
drug design, and perhaps even lead to chemoprevention
for those at high risk of developing HCC.
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